PMID- 18677972
OWN - NLM
STAT- MEDLINE
DCOM- 20080829
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 58
IP  - 6
DP  - 2008
TI  - Effect of an orally active Th2 cytokine inhibitor, suplatast on "atopic cough" 
      tosilate.
PG  - 297-302
LID - 10.1055/s-0031-1296510 [doi]
AB  - BACKGROUND: "Atopic cough" is a new clinical entity that presents with isolated 
      chronic bronchodilator-resistant cough accepted in the Japanese Respiratory 
      Society Guidelines for Management of Cough. The essential features are 
      eosinophilic tracheobronchitis, increased cough reflex sensitivity and an atopic 
      constitution. It has been suggested that activated helper T lymphocytes and the 
      cytokines which are produced by these cells are involved in the pathogenesis, but 
      the relationship between helper T cell-derived cytokines and the airway cough 
      reflex sensitivity remains unknown. METHODS: The effect of an orally active Th2 
      cytokine inhibitor, suplatast tosilate (CAS 94055-76-2, IPD; 300 mg/day), on the 
      cough response to inhaled capsaicin (CAS 404-86-4) was examined in ten patients 
      with atopic cough. The capsaicin cough threshold, defined as the lowest 
      concentration of capsaicin eliciting five or more coughs, was measured as an 
      index of airway cough reflex sensitivity. The serum total immunoglobulin E (IgE) 
      level and the peripheral blood eosinophil count were also determined after 
      treatment with suplatast tosilate. RESULTS: The cough threshold measured after 
      four weeks of treatment with suplatast tosilate was significantly increased 
      compared to the value obtained with placebo, along with a decrease of the serum 
      IgE level and peripheral eosinophil count. CONCLUSIONS: Th2 cytokines may 
      increase the airway cough reflex sensitivity in patients with atopic cough. Oral 
      administration of suplatast tosilate may be a novel therapy for atopic cough.
FAU - Ishiura, Yoshihisa
AU  - Ishiura Y
AD  - Department of Respiratory Medicine, Toyama City Hospital, Toyama, Japan. 
      ishiura-@p2322.nsk.ne.jp
FAU - Fujimura, Masaki
AU  - Fujimura M
FAU - Yamamoto, Hiroki
AU  - Yamamoto H
FAU - Nobata, Kouichi
AU  - Nobata K
FAU - Ishiguro, Takashi
AU  - Ishiguro T
FAU - Ogawa, Haruhiko
AU  - Ogawa H
FAU - Myou, Shigeharu
AU  - Myou S
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Arylsulfonates)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Cytokines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Sulfonium Compounds)
RN  - C9J89787U1 (suplatast tosilate)
RN  - S07O44R1ZM (Capsaicin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Arylsulfonates/*therapeutic use
MH  - Bronchi/drug effects
MH  - Bronchodilator Agents/pharmacology
MH  - Capsaicin
MH  - Cough/chemically induced/*drug therapy
MH  - Cytokines/*biosynthesis
MH  - Drug Resistance
MH  - Eosinophils
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Male
MH  - Middle Aged
MH  - Reflex/drug effects
MH  - Respiratory Function Tests
MH  - Sulfonium Compounds/*therapeutic use
MH  - Th2 Cells/*drug effects/*metabolism
MH  - Vital Capacity/drug effects
EDAT- 2008/08/06 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/08/06 09:00
PHST- 2008/08/06 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/08/06 09:00 [entrez]
AID - 10.1055/s-0031-1296510 [doi]
PST - ppublish
SO  - Arzneimittelforschung. 2008;58(6):297-302. doi: 10.1055/s-0031-1296510.